Genmab A/S (NASDAQ:GMAB) Upgraded by William Blair to “Outperform” Rating

Genmab A/S (NASDAQ:GMAB) was upgraded by investment analysts at William Blair from a “market perform” rating to an “outperform” rating in a research note issued to investors on Tuesday, MarketBeat.com reports. William Blair also issued estimates for Genmab A/S’s FY2028 earnings at $4.06 EPS.

Several other equities research analysts also recently commented on GMAB. HC Wainwright reiterated a “buy” rating and set a $50.00 target price on shares of Genmab A/S in a report on Thursday, January 23rd. Leerink Partnrs upgraded Genmab A/S from a “hold” rating to a “strong-buy” rating in a research report on Thursday, February 13th. BNP Paribas upgraded Genmab A/S from a “strong sell” rating to a “hold” rating in a research report on Tuesday, February 11th. Leerink Partners upgraded Genmab A/S from a “market perform” rating to an “outperform” rating and set a $27.00 price target for the company in a research report on Thursday, February 13th. Finally, Sanford C. Bernstein upgraded Genmab A/S from a “strong sell” rating to a “hold” rating in a report on Friday, December 20th. Four equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $41.33.

Genmab A/S Stock Down 0.2 %

GMAB opened at $20.21 on Tuesday. The firm has a market cap of $13.37 billion, a P/E ratio of 11.61, a PEG ratio of 2.65 and a beta of 0.98. Genmab A/S has a 52 week low of $18.64 and a 52 week high of $31.88. The business’s fifty day simple moving average is $21.28 and its 200 day simple moving average is $22.52.

Genmab A/S (NASDAQ:GMAB) last released its earnings results on Wednesday, February 12th. The company reported $0.57 earnings per share for the quarter, topping the consensus estimate of $0.28 by $0.29. Genmab A/S had a return on equity of 16.78% and a net margin of 36.30%. As a group, equities analysts expect that Genmab A/S will post 1.45 EPS for the current fiscal year.

Institutional Investors Weigh In On Genmab A/S

A number of hedge funds and other institutional investors have recently bought and sold shares of GMAB. EverSource Wealth Advisors LLC boosted its position in Genmab A/S by 295.3% in the 4th quarter. EverSource Wealth Advisors LLC now owns 1,257 shares of the company’s stock valued at $26,000 after buying an additional 939 shares during the last quarter. Lindbrook Capital LLC lifted its holdings in Genmab A/S by 105.4% during the fourth quarter. Lindbrook Capital LLC now owns 1,851 shares of the company’s stock worth $39,000 after acquiring an additional 950 shares in the last quarter. GAMMA Investing LLC lifted its holdings in Genmab A/S by 96.6% during the fourth quarter. GAMMA Investing LLC now owns 2,139 shares of the company’s stock worth $45,000 after acquiring an additional 1,051 shares in the last quarter. Barclays PLC lifted its holdings in Genmab A/S by 1,072.8% during the fourth quarter. Barclays PLC now owns 2,498 shares of the company’s stock worth $52,000 after acquiring an additional 2,285 shares in the last quarter. Finally, Cromwell Holdings LLC raised its stake in shares of Genmab A/S by 656.8% in the 4th quarter. Cromwell Holdings LLC now owns 2,876 shares of the company’s stock valued at $60,000 after purchasing an additional 2,496 shares during the period. 7.07% of the stock is owned by institutional investors and hedge funds.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.